Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Nilotinib Exerts Direct Effects on Vascular Endothelial Cells and May Act As a Co-Trigger of Atherosclerosis in Patients with Ph+ CML

Emir Hadzijusufovic, DVM, Susanne Herndlhofer, Karl J. Aichberger, MD, PhD, Viviane Ghanim, M.D., Verena Suppan, BSc, Sabine Cerny-Reiterer, D.V.M., Wolfgang R Sperr, MD, Peter Valent, M.D.

Blood (2011) 118 (21): 2753.

https://doi.org/10.1182/blood.V118.21.2753.2753

Published: 2011

Journal Articles

Identification of Basophils as Source of Hepatocyte Growth Factor (HGF) In CML: a Potential Trigger of Disease Acceleration.

Sabine Cerny-Reiterer, DVM, Karl J. Aichberger, MD, Harald Herrmann, MD, Gregor Hoermann, MD, Barbara Peter, MVM, Leonhard Muellauer, MD, Matthias Mayerhofer, MD, Peter Valent, MD

Blood (2010) 116 (21): 1202.

https://doi.org/10.1182/blood.V116.21.1202.1202

Published: 2010

Journal Articles

Jak2 V617F Induced TNF Resistance as a Mechanism of Clonal Expansion In Myeloproliferative Neoplasm

Angela G. Fleischman, MD, PhD, Karl J. Aichberger, MD, PhD, Curtis L Petersen, Shirin Doratotaj, MD, Thomas G Bumm, MD, Heike L. Pahl, PhD, Brian J Druker, MD, Michael W Deininger, MD, PhD

Blood (2010) 116 (21): 795.

https://doi.org/10.1182/blood.V116.21.795.795

Published: 2010

Journal Articles

Tumor Necrosis Factor-Alpha (TNF) Expression Is Elevated in Myelo-Proliferative Neoplasms (MPN) and Modulated by Inhibition of JAK2 V617F.

Karl J. Aichberger, MD, PhD, Angela G. Fleischman, MD, PhD, Shirin Doratotaj, MD, Thomas G.P. Bumm, MD, Richard T. Silver, MD, Thomas G. Deloughery, MD, Heike L. Pahl, PhD, Brian J. Druker, MD, Christopher J. Burns, Michael Deininger, MD, PhD

Blood (2009) 114 (22): 2917.

https://doi.org/10.1182/blood.V114.22.2917.2917

Published: 2009

Journal Articles

Effects of the Mcl-1/Bcl-2 Inhibitor GX015-070 (Obatoclax ® ) on Growth and Viability of Canine and Human Neoplastic Mast Cells

Barbara Peter, MVM, Karl J. Aichberger, MD, Karoline V. Gleixner, MD, Veronika Ferenc, MD, Alexander Gruze, Winfried F. Pickl, MD, Michael Willmann, DVM, Peter Valent, MD

Blood (2008) 112 (11): 861.

https://doi.org/10.1182/blood.V112.11.861.861

Published: 2008

Journal Articles

Liposomal Cytarabine (DepoCyte) for Treatment of Myeloid CNS Relapse in CML Occurring during Therapy with Imatinib.

Karl J. Aichberger, MD, MSci, Susanne Herndlhofer, Hermine Agis, MD, Wolfgang R. Sperr, MD, Werner Rabitsch, MD, Harald Esterbauer, MD, PhD, Paul Knoebl, MD, Christian Sillaber, MD, Ulrich Jaeger, MD, Peter Valent, MD

Blood (2007) 110 (11): 4556.

https://doi.org/10.1182/blood.V110.11.4556.4556

Published: 2007

Journal Articles

Synergistic Growth-Inhibitory Effects of Two Tyrosine Kinase Inhibitors, Dasatinib and PKC412, on Neoplastic Mast Cells Expressing the D816V-Mutated Oncogenic Variant of KIT.

Karoline V. Gleixner, MD, Matthias Mayerhofer, MD, Karoline Sonneck, MD, Alexander Gruze, Puchit Samorapoompichit, MD, Karl J. Aichberger, MD, Francis Y. Lee, PhD, Paul W. Manley, PhD, Doriano Fabbro, PhD, Winfried F. Pickl, MD, Christian Sillaber, MD, Peter Valent, MD

Blood (2006) 108 (11): 526.

https://doi.org/10.1182/blood.V108.11.526.526

Published: 2006

Journal Articles

The KIT D816V-Targeting Drug PKC412 Induces Re-Expression of Bim and Synergizes with Mcl-1 Antisense Oligonucleotides in Producing Growth Inhibition in Neoplastic Human Mast Cells.

Karl J. Aichberger, MD, PhD, Matthias Mayerhofer, MD, Karoline V. Gleixner, MD, Maria-Theresa Krauth, MD, Alexander Gruze, Winfried F. Pickl, MD, Volker Wacheck, MD, Edgar Selzer, MD, Christian Sillaber, MD, Peter Valent, MD

Blood (2006) 108 (11): 1437.

https://doi.org/10.1182/blood.V108.11.1437.1437

Published: 2006

Journal Articles

PKC412 Inhibits In Vitro Growth of Neoplastic Mast Cells Expressing the D816V-Mutated Variant of KIT: Comparison with AMN107 and Imatinib, and Evaluation of Drug-Interactions.

Karoline V. Gleixner, MD, Matthias Mayerhofer, MD, Karl J. Aichberger, MD, Sophia Derdak, PhD, Karoline Sonneck, MD, Alexandra Boehm, MD, Puchit Samorapoompichit, MD, Alexander Gruze, Winfried Pickl, Paul Manley, Doriano Fabbro, Christian Sillaber, Peter Valent

Blood (2005) 106 (11): 3523.

https://doi.org/10.1182/blood.V106.11.3523.3523

Published: 2005

Journal Articles

Identification of Mcl-1 as a Novel Target in Neoplastic Mast Cells and Demonstration of Cooperative Growth-Inhibitory Effects of mcl-1 Antisense Oligonucleotides, PKC412, and AMN107.

Karl J. Aichberger, MD, PhD, Matthias Mayerhofer, MD, Karoline V. Gleixner, Maria-Theresa Krauth, MD, Sophia Derdak, PhD, Winfried F. Pickl, MD, Volker Wacheck, MD, Edgar Selzer, MD, Hermine Agis, MD, Christian Sillaber, MD, Peter Valent, MD

Blood (2005) 106 (11): 3516.

https://doi.org/10.1182/blood.V106.11.3516.3516

Published: 2005

Journal Articles

Inhibition of Growth of Neoplastic Mast Cells by CD44 mAb A3D8 Is Associated with G1 Cell Cycle Arrest and Apoptosis.

Alexandra Boehm, MD, Stefan Florian, MD, Karoline Gleixner, Karoline Sonneck, MD, Karl J. Aichberger, MD, Sophia Derdak, PhD, Winfried F. Pickl, MD, Peter Valent, MD, Wolfgang R. Sperr, MD

Blood (2005) 106 (11): 3518.

https://doi.org/10.1182/blood.V106.11.3518.3518

Published: 2005

Journal Articles

In Vitro and In Vivo Antileukemic Effects of the mTOR-Targeting Drug Rapamycin in Patients with Imatinib-Resistant CML.

Matthias Mayerhofer, MD, Alexandra Boehm, MD, Karl J. Aichberger, MD, Harald Esterbauer, MD, PhD, Sophia Derdak, MD, Winfried F. Pickl, MD, Christian Sillaber, MD, Peter Valent, MD

Blood (2005) 106 (11): 4834.

https://doi.org/10.1182/blood.V106.11.4834.4834

Published: 2005

Journal Articles

BCR/ABL Induces Expression of Histidine Decarboxylase and Synthesis of Histamine in CML Cells.

Karl J. Aichberger, MD, PhD, Matthias Mayerhofer, MD, Maria-Theresa Krauth, MD, Anna Vales, MD, Sophia Derdak, PhD, Winfried F. Pickl, MD, Christian Sillaber, MD, Peter Valent, MD

Blood (2005) 106 (11): 4835.

https://doi.org/10.1182/blood.V106.11.4835.4835

Published: 2005

Journal Articles

Low-Level Expression of the Tumor Suppressor Bim in CML Cells: Role of BCR/ABL, Delineation of Underlying Signaling Pathways, and Re-Expression by Imatinib, AMN107, and Proteasome Inhibitors.

Karl J. Aichberger, MD, PhD, Matthias Mayerhofer, MD, Maria-Theresa Krauth, MD, Anna Vales, MD, Sophia Derdak, PhD, Winfried F. Pickl, MD, Edgar Selzer, MD, Michael Deininger, MD, PhD, Brian J. Druker, MD, Christian Sillaber, MD, Peter Valent, MD

Blood (2005) 106 (11): 1987.

https://doi.org/10.1182/blood.V106.11.1987.1987

Published: 2005

Journal Articles

c-kit D816V Provides a Strong Signal for Myelomastocytic Differentiation and Cluster Formation in Murine Ba/F3 Cells.

Matthias Mayerhofer, MD, Karl J. Aichberger, MD, Stefan Florian, Maria-Theresa Krauth, MD, Martin Bilban, PhD, Harald Esterbauer, MD, PhD, Oswald Wagner, MD, Reinhard Kodym, MD, Karl Sotlar, MD, Jack B. Longley, MD, Hans-Peter Horny, MD, Christian Sillaber, MD, Peter Valent, MD

Blood (2004) 104 (11): 485.

https://doi.org/10.1182/blood.V104.11.485.485

Published: 2004

Journal Articles

Targeting of mTOR in AML Is Associated with Decreased Growth of Leukemic Cells and Downregulation of VEGF.

Alexandra Boehm, MD, Karl J. Aichberger, MD, Matthias Mayerhofer, MD, Maria-Theresa Krauth, MD, Sophia Derdak, PhD, Winfried F. Pickl, MD, Puchit Samorapoompichit, MD, Christian Sillaber, MD, Stefan Florian, Karoline Sonneck, MD, Wolfgang R. Sperr, MD, Peter Valent, MD

Blood (2004) 104 (11): 2544.

https://doi.org/10.1182/blood.V104.11.2544.2544

Published: 2004

Journal Articles

Cooperative Anti-Leukemic Effects of Imatinib and Mcl-1 Antisense: Identification of Mcl-1 as a Novel Target in CML.

Karl J. Aichberger, MD, Matthias Mayerhofer, MD, Maria-Theresa Krauth, MD, Hans Skvara, MD, Stefan Florian, MD, Karoline Sonneck, MD, Cahit Akgul, MD, Sophia Derdak, PhD, Winfried F. Pickl, MD, Volker Wacheck, MD, Edgar Selzer, MD, Brett P. Monia, PhD, Richard Moriggl, PhD, Peter Valent, MD, Christian Sillaber, MD

Blood (2004) 104 (11): 2972.

https://doi.org/10.1182/blood.V104.11.2972.2972

Published: 2004

Journal Articles

Histidine Decarboxylase (HDC) as Novel Marker of Immature Neoplastic Mast Cells in Systemic Mastocytosis.

Maria T. Krauth, md, Hermine Agis, md, Karl J. Aichberger, md, Ingrid Simonitsch, md, Leonhard Muellauer, md, Matthias Mayerhofer, md, Hans P. Horny, md, Peter Valent, md

Blood (2004) 104 (11): 4755.

https://doi.org/10.1182/blood.V104.11.4755.4755

Published: 2004

Journal Articles

The Heme Oxygenase-1-Targeting Compound PEG-ZnPP Inhibits Growth of Imatinib-Resistant BCR/ABL-Transformed Cells.

Matthias Mayerhofer, MD, Karl J. Aichberger, MD, Stefan Florian, Maria-Theresa Krauth, MD, Sophia Derdak, PhD, Harald Esterbauer, PhD, MD, Oswald Wagner, MD, Winfried F. Pickl, MD, Edgar Selzer, MD, Michael W. Deininger, PhD, MD, Brian J. Druker, MD, Khaled Greish, PhD, Hiroshi Maeda, MD, Christian Sillaber, MD, Peter Valent, MD

Blood (2004) 104 (11): 1986.

https://doi.org/10.1182/blood.V104.11.1986.1986

Published: 2004

NARROW

Nilotinib Exerts Direct Effects on Vascular Endothelial Cells and May Act As a Co-Trigger of Atherosclerosis in Patients with Ph+ CML

Identification of Basophils as Source of Hepatocyte Growth Factor (HGF) In CML: a Potential Trigger of Disease Acceleration.

Jak2 V617F Induced TNF Resistance as a Mechanism of Clonal Expansion In Myeloproliferative Neoplasm

Tumor Necrosis Factor-Alpha (TNF) Expression Is Elevated in Myelo-Proliferative Neoplasms (MPN) and Modulated by Inhibition of JAK2 V617F.

Effects of the Mcl-1/Bcl-2 Inhibitor GX015-070 (Obatoclax ® ) on Growth and Viability of Canine and Human Neoplastic Mast Cells

Liposomal Cytarabine (DepoCyte) for Treatment of Myeloid CNS Relapse in CML Occurring during Therapy with Imatinib.

Synergistic Growth-Inhibitory Effects of Two Tyrosine Kinase Inhibitors, Dasatinib and PKC412, on Neoplastic Mast Cells Expressing the D816V-Mutated Oncogenic Variant of KIT.

The KIT D816V-Targeting Drug PKC412 Induces Re-Expression of Bim and Synergizes with Mcl-1 Antisense Oligonucleotides in Producing Growth Inhibition in Neoplastic Human Mast Cells.

PKC412 Inhibits In Vitro Growth of Neoplastic Mast Cells Expressing the D816V-Mutated Variant of KIT: Comparison with AMN107 and Imatinib, and Evaluation of Drug-Interactions.

Identification of Mcl-1 as a Novel Target in Neoplastic Mast Cells and Demonstration of Cooperative Growth-Inhibitory Effects of mcl-1 Antisense Oligonucleotides, PKC412, and AMN107.

Inhibition of Growth of Neoplastic Mast Cells by CD44 mAb A3D8 Is Associated with G1 Cell Cycle Arrest and Apoptosis.

In Vitro and In Vivo Antileukemic Effects of the mTOR-Targeting Drug Rapamycin in Patients with Imatinib-Resistant CML.

BCR/ABL Induces Expression of Histidine Decarboxylase and Synthesis of Histamine in CML Cells.

Low-Level Expression of the Tumor Suppressor Bim in CML Cells: Role of BCR/ABL, Delineation of Underlying Signaling Pathways, and Re-Expression by Imatinib, AMN107, and Proteasome Inhibitors.

c-kit D816V Provides a Strong Signal for Myelomastocytic Differentiation and Cluster Formation in Murine Ba/F3 Cells.

Targeting of mTOR in AML Is Associated with Decreased Growth of Leukemic Cells and Downregulation of VEGF.

Cooperative Anti-Leukemic Effects of Imatinib and Mcl-1 Antisense: Identification of Mcl-1 as a Novel Target in CML.

Histidine Decarboxylase (HDC) as Novel Marker of Immature Neoplastic Mast Cells in Systemic Mastocytosis.

The Heme Oxygenase-1-Targeting Compound PEG-ZnPP Inhibits Growth of Imatinib-Resistant BCR/ABL-Transformed Cells.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only